Response to “Comment on E-Cigarettes and Cardiovascular Risk: Beyond Science and Mysticism”

Giuseppe Lippi, MD1  Gianfranco Cervellin, MD2  Emmanuel J. Favaloro, PhD, FFSc (RCPA)3

1 Laboratory of Clinical Chemistry and Hematology, Academic Hospital of Parma, Parma, Italy
2 Emergency Department, Academic Hospital of Parma, Parma, Italy
3 Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, New South Wales, Australia

Address for correspondence Giuseppe Lippi, MD, U.O. Diagnostica Ematochimica, Azienda Ospedaliero-Universitaria di Parma, Via Gramsci, 14, 43126 Parma, Italy (e-mail: glippi@ao.pr.it; ulippi@tin.it).


The letter referring to our article1 on the effect of electronic cigarettes (e-cigarette) on human health by Farsalinos et al is both interesting and of value.2 The authors basically argue against two issues that we discussed in our previous narrative review, that is, the cardiovascular risk attributable to nicotine and the effective toxicity of liquid nicotine present in e-cigarettes. Besides the fact that the biological evidence available on e-cigarette smoking remains to date rather limited, some aspects need to be highlighted.

As regard the effect of nicotine on cardiovascular risk, two of the articles used by Farsalinos et al2 in support of a lack of plausible connection are fairly dated, being respectively published in 1996 and 1998.3,4 A more recent meta-analysis on smokeless tobacco and risk of myocardial infarction and stroke published by Boffetta and Straif in 2009 concluded that the relative risk for ever use of smokeless tobacco products was 1.13 (95% confidence interval [95% CI], 1.06–1.21) for myocardial infarction and 1.40 (95% CI, 1.28–1.54) for fatal stroke.5 Also, at variance with what is stated in their correspondence,2 data about the cardiovascular potential of nicotine are contradictory. Besides episodic case reports of patients developing acute myocardial infarction while using nicotine patches,6,7 additional population studies described a high rate of cardiovascular complications in patients using these sticking plasters.8,9 Even from a biological perspective, the statement that nicotine has minimal effects in initiating and propagating atherosclerosis is questionable, as recent studies have shown that this compound binds to nicotinic acetylcholine receptors and accelerates the atherogenic process.10 Therefore, although we would agree that nicotine replacement therapies (NRTs) present a lesser hazard than continuing to smoke because there exists unquestionable data supporting that use of NRTs carries much lower risks than traditional tobacco smoking, our leading concern relates to the potential health effects of these devices on adolescent and nonsmokers.11 After decades of effective work to reduce cigarette smoking, the widespread availability of e-cigarettes raises the question of whether these devices are reintroducing a form of smoking to many adolescents, who may respond positively to advertising claims that e-cigarettes are safe.12 Once accustomed to e-cigarettes use, they may then be subjected to adverse side effects of these devices or, even worse, prompted to shift to traditional tobacco smoking.

We also dispute the statement by the authors2 that we have exaggerated the toxicity of liquid nicotine present in e-cigarettes. The number of case reports regarding toxicity of nicotine-containing solutions is constantly growing in the scientific literature.13–16 Moreover, a recent study investigating the nicotine concentration of several nicotine-containing solutions has concluded that these mixtures could be toxic or lethal if taken other than as directed, even at potentially lower levels of nicotine than expected using manufacturer specifications.17,18

In conclusion, although we respect the points of view raised by Farsalinos et al,2 at this point in time it seems premature and potentially hazardous to conclude that e-cigarette use and/or nicotine intake are unlikely to significantly elevate harm. Major caution should be observed until the outcome of randomized, prospective studies on e-cigarette use become available.

Copyright © 2014 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.
Tel: +1(212) 584-4662.
ISSN 0094-6176.
Conflict of Interest
One of the authors (E.J.F.) is the Editor in Chief of this journal. There are no other conflicts of interest. None of the authors have received any funding support from manufacturers of tobacco or "smokeless-tobacco" or associated products.

References

Seminars in Thrombosis & Hemostasis Vol. 40 No. 4/2014
Letter to the Editor